Navigation Links
To evade chemotherapy, some cancer cells mimic stem cells
Date:9/19/2007

ATLANTA - Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented today in Atlanta, Georgia at the American Association for Cancer Researchs second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

Our experiments suggest that some treatments could be producing more cancer stem cells that then are capable of metastasizing, because these cells are trying to find a way to survive the therapy, said one of the studys investigators, Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences in Bethesda, Md.

This may help explain why the expression of stem cell markers has been associated with resistance to chemotherapy and radiation treatments and poor outcome for patients with cancers including prostate, breast and lung cancers, Dr. Vasko said. That tells us that understanding how to target these markers and these cells could prove useful in treating these cancers.

The cancer stem cell markers include Nanog and BMI1, both of which contribute to stem cells defining ability to renew themselves and differentiate into different cell types, Dr. Vasko said. These same molecules are found in embryonic stem cells.

Researchers have recently debated the notion that some therapies are not capable of eradicating cancer because they do not target the cancer stem cells responsible for tumor development. To test this hypothesis, Dr. Vasko, along with scientists from the CRTRC Institute for Drug Development in San Antonio and from the Johns Hopkins University, set out to measure both stem cells markers and tumor volume before and after treatment in a mouse model.

They selected a rare form of cancer, mesenchymal chondrosarcoma (MCS), which has not been well described and for which there is no effective treatment. The researchers first determined that Nanog and BMI1 stem cell markers were more highly expressed in metastatic tumors compared to primary tumors. This suggests that expression of the marker plays some role in development of metastasis, Dr. Vasko said.

They then applied various therapies - from VEGF inhibitors such as Avastin to the proteasome inhibitor Velcade - in mice implanted with human MSC, and analyzed the effects on tumors. Some of the treatments seemed to work, because they led to a dramatic decrease in the size of the tumors, Dr. Vasko said. But analysis of stem cell expression before and after treatment revealed that even as some anti-cancer treatments shrank tumors, they increased expression of Nanog and BMI1. These treatments were not enough to completely inhibit tumor growth, and the cancer stem cell markers were still present, Dr. Vasko said.

Use of the agents Velcade and Docetaxel led to the most significant increase in stem cell markers within the treated tumor, while ifosfamide and Avastin inhibited expression of the markers in this cancer subtype.

We hypothesize that the tumor escapes from chemotherapy by induction of stem cell marker expression, he said. The small number of cells that survive the treatment could then generate another tumor that metastasizes.

Dr. Vasko doesnt know how this happens, but theorizes that dying cells could secrete a lot of factors that induce expression of stem cell markers in other cancer cells. I think they are trying to survive and they use a mechanism from their experience of embryonic life.


'/>"/>

Contact: Greg Lester
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Herpes Infects Cornea, Evades Immune Cells
2. Researchers Discover How Cancer Evades the Immune System
3. Radiation And Chemotherapy, A Better Option For Head And Neck Cancer
4. Watchdog to Be Set on Oral Chemotherapy, Warns Experts
5. Fibroids unlikely to Turn Cancerous
6. Virus Level could Predict Cervical Cancer Risk
7. Cancer Doctors Okays Controversial Prostate Therapy
8. Potential New Cancer Gene Identified
9. Vitamin B12 can help in detecting cancers
10. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
11. Consensus on "Combination Therapy" for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... NEW ORLEANS, La. (PRWEB) , ... July 21, ... ... tool to allow 4th-year medical students improve their chances of acceptance to a ... particularly for those who have earned degrees outside the U.S. , According to ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is proud of ... her research center at Bio-Logic Aqua Research® Water Life Science®, has been released ... of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... insight into why concussion rates are on the rise, say researchers presenting their ... today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns of ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: